Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving virus or bacteriophage
Reexamination Certificate
2007-12-04
2008-12-02
Mosher, Mary E (Department: 1648)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving virus or bacteriophage
C424S199100, C424S208100, C424S232100, C424S281100, C435S235100, C435S236000, C435S320100
Reexamination Certificate
active
07459270
ABSTRACT:
The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus and characterized by the loss of its capability to reproductively replicate in human cell lines. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised. In addition, a method is provided for the administration of a therapeutically effective amount of the virus, or its recombinants, in a vaccinia virus prime/vaccinia virus boost inoculation regimen.
REFERENCES:
patent: 3914408 (1975-10-01), Mebus
patent: 4072565 (1978-02-01), Weiss et al.
patent: 4191745 (1980-03-01), Mayr et al.
patent: 5155020 (1992-10-01), Paoletti
patent: 5185146 (1993-02-01), Altenburger
patent: 5338683 (1994-08-01), Paoletti et al.
patent: 5403582 (1995-04-01), Nazerian et al.
patent: 5405772 (1995-04-01), Ponting
patent: 5494807 (1996-02-01), Paoletti et al.
patent: 5597570 (1997-01-01), Sondermeyer et al.
patent: 5676950 (1997-10-01), Small et al.
patent: 5753489 (1998-05-01), Kistner et al.
patent: 5756341 (1998-05-01), Kistner et al.
patent: 5770212 (1998-06-01), Falkner et al.
patent: 5789245 (1998-08-01), Chang et al.
patent: 5843456 (1998-12-01), Paoletti et al.
patent: 6190655 (2001-02-01), Lyman et al.
patent: 6204250 (2001-03-01), Bot et al.
patent: 6440422 (2002-08-01), Sutter et al.
patent: 6497883 (2002-12-01), Bublot et al.
patent: 6605465 (2003-08-01), Paoletti
patent: 6663871 (2003-12-01), McMichael et al.
patent: 6685950 (2004-02-01), Weber et al.
patent: 6761893 (2004-07-01), Chaplin et al.
patent: 6805870 (2004-10-01), Mayr
patent: 6869793 (2005-03-01), Cardosa et al.
patent: 6913752 (2005-07-01), Chaplin et al.
patent: 6976752 (2005-12-01), Parish et al.
patent: 7056723 (2006-06-01), Heller et al.
patent: 7097842 (2006-08-01), Suter et al.
patent: 2002/0022268 (2002-02-01), Xu et al.
patent: 2003/0013190 (2003-01-01), Mayr
patent: 2003/0138454 (2003-07-01), Hill et al.
patent: 2003/0206926 (2003-11-01), Chaplin et al.
patent: 2003/0228330 (2003-12-01), Falkner et al.
patent: 2004/0131594 (2004-07-01), McMichael et al.
patent: 2005/0214323 (2005-09-01), Chaplin et al.
patent: 2005/0271688 (2005-12-01), Chaplin et al.
patent: 2006/0029619 (2006-02-01), Howley et al.
patent: 2006/0127984 (2006-06-01), Ackermann et al.
patent: 2006/0159699 (2006-07-01), Howley et al.
patent: 2006/0165727 (2006-07-01), Howley et al.
patent: 2006/0280758 (2006-12-01), Chaplin et al.
patent: 1586330 (2005-10-01), None
patent: 2 603 040 (1986-08-01), None
patent: 2370573 (2002-07-01), None
patent: PA01012723 (2002-06-01), None
patent: WO 90/12882 (1990-11-01), None
patent: WO 92/05246 (1992-04-01), None
patent: WO 95/22978 (1995-08-01), None
patent: WO 97/02355 (1997-02-01), None
patent: WO 97/31119 (1997-08-01), None
patent: WO 98/04680 (1998-02-01), None
patent: WO 98/17283 (1998-04-01), None
patent: WO 98/56919 (1998-12-01), None
patent: WO 99/07869 (1999-02-01), None
patent: WO 00/28016 (2000-05-01), None
patent: WO 0029428 (2000-05-01), None
patent: WO 01/68820 (2001-09-01), None
patent: WO 01/89559 (2001-11-01), None
patent: WO 02/24224 (2002-03-01), None
patent: WO 02/42480 (2002-05-01), None
Carroll, et al. Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a Murine tumor model. Vaccine, 1997; vol. 15, No. 4, pp. 387-394.
Disis and Cheever. HER-2
eu protein: a target for antigen-specific immunotherapy of human cancer. Adv Cancer Res. 1997;71:343-71. Abstract Only.
Mulryan, et al.Attenuated Recombinant Vaccinia Virus Expressing Oncofetal Antigen (Tumor-associated Antigen) 5T4 Induces Active Therapy of Established Tumors. Molecular Cancer Therapeutics. 2002; vol. 1, 1129-1137.
In the matter of: Certain Modified Vaccinia Ankara (“MVA”) Viruses and Vaccines and Pharmaceutical Compositions Based Thereon, Investigation No. 337-TA-550, Order No. 28:Denying in Part Complainant's Motion for Summary Determination and Denying in Part Respondent's Motion for Summary Determination, United States International Trade Commission, Washington, D.C., Apr. 18, 2006.
In the matter of: Certain Modified Vaccinia Ankara (“MVA”) Viruses and Vaccines and Pharmaceutical Compositions Based Thereon, Investigation No. 337-TA-550,Nucleotide alignment of MVA-AntionevsAcambia 3000 MVAvsMVA-BN, Aug. 31, 2005.
In the matter of: Certain Modified Vaccinia Ankara (“MVA”) Viruses and Vaccines and Pharmaceutical Compositions Based Thereon, Investigation No. 337-TA-550,Respondent's Amended Pre-Hearing Brief, United States International Trade Commission, Washington, D.C., May 8, 2006.
In the matter of: Certain Modified Vaccinia Ankara (“MVA”) Viruses and Vaccines and Pharmaceutical Compositions Based Thereon, Investigation No. 337-TA-550,Respondent's Opposition to Compainant's Motion for Sanctions, United States International Trade Commission, Washington, D.C., Jul. 7, 2006.
In the matter of: Certain Modified Vaccinia Ankara (“MVA”) Viruses and Vaccines and Pharmaceutical Compositions Based Thereon, Investigation No. 337-TA-550.Respondent's Opposition to Compainant's Motion for Summary Determination of Infringement, 10439953.051603 United States International Trade Commission, Washington, D.C., 2006.
In the matter of: Certain Modified Vaccinia Ankara (“MVA”) Viruses and Vaccines and Pharmaceutical Compositions Based Thereon, Investigation No. 337-TA-550,Respondent's Rebuttal to Compainant's Proposed Conclusions of Law, United States International Trade Commission, Washington, D.C., Jun. 14, 2006.
In the matter of: Certain Modified Vaccinia Ankara (“MVA”) Viruses and Vaccines and Pharmaceutical Compositions Based Thereon, Investigation No. 337-TA-550,Compainant Bavarian Nordic's Motion for Sanctions and Memorandum in Support of Its Motion, United States International Trade Commission, Washington, D.C., Jun. 21, 2006 (Public Version).
In the matter of: Certain Modified Vaccinia Ankara (“MVA”) Viruses and Vaccines and Pharmaceutical Compositions Based Thereon, Investigation No. 337-TA-550,Memorandum in Opposition to Respondent's Motion for Summary Determination, United States International Trade Commission, Washington, D.C., Mar. 30, 2006 (Public Version).
In the matter of: Certain Modified Vaccinia Ankara (“MVA”) Viruses and Vaccines and Pharmaceutical Compositions Based Thereon, Investigation No. 337-TA-550,Compainant Bavarian Nordic's Memorandum in Support of Its Motion in Limine, United States International Trade Commission, Washington, D.C., May 1, 2006 (Public Version).
In the matter of: Certain Modified Vaccinia Ankara (“MVA”) Viruses and Vaccines and Pharmaceutical Compositions Based Thereon, Investigation No. 337-TA-550,Compainant's Post Hearing Brief, United States International Trade Commission, Washington, D.C., Apr. 28, 2006 (Public Version).
In the matter of: Certain Modified Vaccinia Ankara (“MVA”) Viruses and Vaccines and Pharmaceutical Compositions Based Thereon, Investigation No. 337-TA-550,Compainant Bavarian Nordic's Motion for Summary Determination of Infringement of the '893 Patent, Its Memorandum of Law in Support of Its Motion, Its Statement of Undisputed Facts in Support of Its Motion and Supporting Exhibits, United States International Trade Commission, Washington, D.C., Mar. 20, 2005 (Public Version).
In the matter of: Certain Modified Vaccinia Ankara (“MVA”) Viruses and Vaccines and Pharmaceutical Compositions Based Thereon, Investigation No. 337-TA-550,Compainant's Post Hearing Reply Brief, United States International Trade Commission, Washington, D.C., Jun. 14, 2006 (Public Version).
Bender, et al., Oral Immunization with a Replication-Deficient Recombinant Vaccinia Virus Protects Mice Against Influenza. (1996) J. Virology, vol. 70(9):6418-6424.
Jax® Mice Data Sheet, Product Information for Stock No. 001913, The Jackson Lab
Chaplin Paul
Howley Paul
Meisinger-Henschel Christine
Bavarian Nordic A/S
Law Office of Salvatore Arrigo
Mosher Mary E
Snyder Stuart W
LandOfFree
Modified Vaccinia Ankara virus variant does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modified Vaccinia Ankara virus variant, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified Vaccinia Ankara virus variant will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4046277